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In the last few years there has been growing excite-
ment about the ‘molecular revolution’ that seems to
offer both a promise and a threat at the same time.
As more and more diseases are shown by research
to be linked to a genetic cause, the field of preven-
tion will potentially be revolutionized: genetic re-
search has highlighted the fact that the conditions
depending on the genetic makeup of a person are
much more than the traditionally known Mendelian
diseases, and range from metabolic disorders to sus-
ceptibility to certain types of cancer. In addition to
this, it is well known that most of diseases causing
disability and death in the western world are chronic
diseases, best dealt with through prevention rather
than treatment. There are few doubts that future
medicine will move in the direction of “testing be-
fore” rather than “curing after”. In this scenario, the
healthcare system of the next decades will be able
to dispense with most of the clinical activity as we
know it today, as genetic knowledge will provide a
“gateway” for referring patients to the form of treat-
ment most adequate to each individual case. As a
result, physicians will probably have to face the
challenge of playing a completely new role.
However, so far, genetic knowledge has affected
only marginally the everyday practice of medical
professionals, who therefore run the risk of being
“overcome” by their sudden impact in the near fu-
ture. An opportunity to reflect upon genetic tech-
nologies and their impact on the medical profession
was provided by the International Workshop held
on September 22nd at the Ospedale della Versilia,
within the 3rd edition of the Viareggio Health
Festival. This year’s Festival had the title “Genetic
Testing and Hereditary Diseases: Between the Right
not to Know and the Duty to Inform”, and was
aimed to investigate the ethical and legal aspects of
medical genetic information, and the establishment
of proper ways of handling it within the patient-
clinician relationship.
The first form of genetic knowledge is the determin-
istic one that exists in the case of Mendelian dis-
eases like cystic fibrosis or chromosomal abnormal-
ities such as the Down syndrome. These diseases
cannot be cured, but the presence of the chromoso-
mal or genetic abnormality can be established be-
fore birth by performing a test on the pregnant
woman. In Italy, the law (DM 10/10/98, D. lgs. 229-
10/06/1999, “Decreto Bindi”) has established that
all pregnant women considered to be in a risk cate-
gory - familial or age-related - have the right to free
access to the test, leaving it to each region to set up
specific screening programs. The tests in question
are invasive and represent a risk for the pregnancy;
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9 therefore they are not suited for population-wide
screening programs. In recent years, however, tech-
nical advances have made a non-invasive test pos-
sible, at least for the Down syndrome, by examining
fetal proteins in maternal serum [1]. At present,
non-invasive tests are not reliable on their own but
they could be effective as a screening method (first
step) for the pre-selection of candidates for the inva-
sive tests, and for this reason they could be offered
on a routine basis, as is already happening in some
countries, namely the UK. A further reason why the
management of prenatal genetic testing could move
in this direction is that - at least in Italy - maternal
age is no longer considered a satisfactory discrimi-
nator given the constant rise of the age of first preg-
nancy in Italian women [1]. 
Indeed, some of the presentations at the workshop
dealt with the ethical consequences of prenatal test-
ing. Matti Häyry and Tujia Takala from the
University of Helsinki conducted a philosophic and
historical analysis of the concept of parental rights
and the form they have taken in different societal
models. They argued that genetic screening em-
powers prospective parents, increasing their rights
in reproductive matters. Societal interference upon
the reproductive act is at the same time lessened, a
result which is generally considered fair in liberal
societies. On the other hand, Rebecca Bennett from
the University of Manchester warned in her lecture
that making prenatal tests routine might exert coer-
cive pressure on those women who might not want
to know their future child’s makeup. Since the ge-
netic condition cannot be cured, in most cases the
information provided by the test only leaves the
prospective parents with the painful choice of abor-
tion or not. It is for this reason that prenatal genetic
tests are criticized as “not preventing harm but pre-
venting children”. Bennett argued that, while testing
does not actually bring any advantage to women or
to their children, the routine setting causes the test
to be perceived as something beneficial. Of course
Bennett’s point is not about advocating a ‘blissful
ignorance’ about genetic conditions: what she con-
tended is that routine prenatal genetic tests may not
be the best possible use of public funds, given that
they do not result in beneficial effects either for the
mother or child while, at the same time, they might
be infringing upon the woman’s ‘right not to know’.
It was to a close scrutiny - philosophical, ethical
and legal - of this ‘right not to know’ that most of the
meeting was devoted. Apart from the case men-
tioned above of a possible desire not to know genet-
ic information about one’s yet unborn child, this
notion is classically applied to genetic information
about one’s own self regarding late onset diseases -
Huntington’s disease to name one – or conditions
that imply only an increased risk or susceptibility
for a disease. The best known instance of this latter
case is probably represented by the pair of BRCA
mutations that are involved in familiar breast can-
cer; however, BRCA mutations are just the leader of
a pack of genetic alterations that have been identi-
fied so far and that have a widely variable degree of
correlation with increased risk for many types of
cancer. The level of increased susceptibility associ-
ated with BRCA mutations is high enough to push
many women who test positive to BRCA to have
prophylactic mastectomy. The problem is that at the
moment medicine has not much more to offer in
this field in terms of prevention, hence it is under-
standable that people may prefer not to have the in-
formation about their genetic alterations - particu-
larly if the associated risk is low - in order to avoid
the additional worries and anxieties posed by infor-
mation which is in any case only probabilistic. On
the other hand, some might want to have this infor-
mation in order to better plan their life and to take
informed decisions about their future. The problem,
at this point, is that genetic information is shared
between family members; therefore the information
about one’s genetic makeup generally brings with it
information about the makeup of parents or siblings
who may instead not want to know. How should
physicians deal with the right not to know? Should
they respect it, or are there over-ruling considera-
tions? A well known challenge to the right of a per-
son to remain in ignorance is the objection that
knowledge is a form of empowerment; therefore ig-
norance about relevant aspects of one’s health
would undermine the person's autonomy and capa-
bility to plan their future life in an informed way.
This in turn could be perceived as an additional bur-
den on the shoulders of the practitioner, who may
feel they are responsible for their patient’s unin-
formed choices.
Lisa Bortolotti from the University of Birmingham
took up precisely this point in her lecture. Drawing
an analogy between the form of self-knowledge
represented by genetic information and that associ-
ated with psychological features, she concluded
that not knowing does not imply by necessity an im-
pairment of personal autonomy. But can a guide-
line, or a default state, be chosen regarding whether
information should be given to patients? Matteo
Mameli from King’s College, London, confronted
this in his lecture. Clearly, the default cannot be
withholding the information, since this attitude
would be unacceptably paternalistic and patently
harming the interest of the patient. However, the
option cannot be to inform by default either, since
in this case the interest of those who do not want to
know would be infringed. The right not to know in-
deed configures itself more as an interest, or a 
prima facie right that can be overridden by other
considerations and particularly other people’s rights
and interests. It is ultimately a legal matter to define
the boundaries and the most appropriate forms of
realization of this right: this legal analysis was un-
dertaken by Roberto Andorno from the University of
Zurich. At the EU level, the right not to know is out-
lined in the framework of the Oviedo convention,
within Art. 10.2 “Everyone is entitled to know any
information collected about his or her health.
However, the wishes of individuals not to be so in-
formed shall be observed” and in Art. 10.3 “In ex-
ceptional cases, restrictions might be placed by law
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on the exercise of the rights contained in paragraph
2 in the interest of the patient”. 
As we see, the Convention states the right not to
know in the same terms that emerged from the dis-
cussion reported above: as an interest of people that
ought to be respected, but that can be overridden in
consideration of other factors. In general in almost
all legal settings the right or, better, interest of a per-
son not to know is honoured under the condition
that no harm results to others, and that such interest
has been made explicit.
There is an additional facet of genetic information,
one that is probably not so familiar to the Italian
public. It is the case of Direct-to-consumer genetic
tests (DTCs) that are offered in the US by private
companies, which advertise and market them gen-
erally online, completely outside the clinical set-
ting. What these companies offer is the possibility to
send a biological sample and have it analyzed, ob-
taining at the end of the process a personal table
with the risk factors determined from genetic data
for a number of diseases. The main problem is that,
contrary to what happens for pharmaceutical prod-
ucts, there is at the moment very little supervision of
the marketing of genetic tests. The need for regula-
tion was perceived only recently, when one of the
companies offering this service, Pathway Genomics,
announced its intention to make its test kit available
in a big retail chain. Concerns voiced by many parts
upon this announcement prompted the FDA to
make a concrete plan for the regulation of genetic-
testing companies [2]. What is at issue is the clinical
utility of these tests, i.e. the fact that the benefits
they provide may not be enough to outweigh the
risks. The risk in this case is to have patients left to
make complex medical decisions without coun-
selling and support from healthcare professionals.
In fact, even if the tests offered are totally reliable
and the results presented are aligned to state-of-the-
art genomic knowledge, there is still the problem
that the information that the test client receives is
probabilistic. The data that are given are in fact per-
centages of an increase/decrease of risk with re-
spect to a reference population, information which
is admittedly difficult to interpret, particularly so for
the non-specialist. And yet genetic testing compa-
nies do not offer any kind of counselling on the re-
sults: patients have to seek healthcare professionals
for help with the interpretation. 
In the latest issue of the New England Journal of
Medicine, two comments dealt with the possibili-
ties and risks posed by the so-called “Consumer-dri-
ven Genomic Age” [3-4]. In the scenario in which
genetic medicine would be fuelled by the individ-
ual patient’s private initiative, the role of healthcare
professionals in this field would be likewise re-
duced to counselling and follow up on the results of
the genetic test. DTCs have recently appeared in
Italy in a context that is cosmetic rather than strictly
medical. An international company does in fact of-
fer through chemist’s shops the possibility to be test-
ed for one’s ‘metabolic profile’, in order to get per-
sonalized dietary advice based on genetic informa-
tion on metabolism. It is still open to development
whether DTC in Italy will remain at this level of cos-
metic application or if it will be extended to more
comprehensive health aspects like the situation is in
the US.
A further impulse in this direction is the fact that,
under the current trend, the cost of sequencing
technology is continuously shrinking and it is possi-
ble to foresee that in the not too distant future full
access to one’s own genetic information will be
within the possibilities of a sizeable portion of the
population in wealthy industrialized countries. On
this aspect the last speaker, Søren Holm from the
University of Manchester, focused attention in his
lecture entitled ‘The 1000$ genome and the duty
not to worry (too much)’. He stressed the fact that
virtually every person carries in their own genome
at least one allele that is a putative risk factor for
common diseases: there is an effective problem
about how this information could negatively affect
people’s lives if not properly managed. Actually, ge-
netic information is less relevant than other factors
for people’s health: however, this message has to be
passed on to the public and to physicians. Genetic
counselling is likely to cost more than genome se-
quencing in the future, and it is equally likely that
the onus to provide it will be on the traditional
healthcare providers’ shoulders.
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